220 filings
DEFA14A
COLL
Collegium Pharmaceutical Inc
10 May 24
Additional proxy soliciting materials
8:03am
8-K
COLL
Collegium Pharmaceutical Inc
10 May 24
Departure of Directors or Certain Officers
8:02am
10-Q
2024 Q1
COLL
Collegium Pharmaceutical Inc
Quarterly report
9 May 24
4:07pm
8-K
COLL
Collegium Pharmaceutical Inc
9 May 24
Collegium Reports First Quarter 2024 Financial Results
4:04pm
8-K
COLL
Collegium Pharmaceutical Inc
29 Apr 24
Entry into a Material Definitive Agreement
8:05am
8-K
9ul1tt9xnk9dp df6071
11 Apr 24
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
8:00am
ARS
o6k3m5blrdds
5 Apr 24
Annual report to shareholders
4:03pm
DEFA14A
o50xk0uc c2
5 Apr 24
Additional proxy soliciting materials
4:03pm
8-K
ehlc4de
22 Feb 24
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
4:01pm
8-K
2k30x 06j2hf
3 Jan 24
Regulation FD Disclosure
8:03am
8-K
4l5bs 9z6
9 Nov 23
Other Events
8:05am
8-K
0brknba6k c2vv
7 Nov 23
Collegium Reports Third Quarter 2023 Financial Results
4:01pm
8-K
rp76qtn 95pu
24 Aug 23
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
8:05am
S-8
522m 2zl4mv7amygw
10 Aug 23
Registration of securities for employees
4:06pm
8-K
zdu8q4w
7 Aug 23
Other Events
7:40am
8-K
xm973g7v 0eru5bv39
3 Aug 23
Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year
4:03pm